| Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement PJ Neumann, JD Chambers, F Simon, LM Meckley Health Affairs 30 (12), 2329-2337, 2011 | 132 | 2011 |
| Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss NR Barshes, JD Chambers, J Cohen, M Belkin, ... Journal of vascular surgery 56 (4), 1015-1024. e1, 2012 | 105 | 2012 |
| The promise of Immuno-oncology: implications for defining the value of cancer treatment HL Kaufman, MB Atkins, P Subedi, J Wu, J Chambers, T Joseph Mattingly, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 87 | 2019 |
| Does Medicare have an implicit cost-effectiveness threshold? JD Chambers, PJ Neumann, MJ Buxton Medical Decision Making 30 (4), E14-E27, 2010 | 86 | 2010 |
| Listening to Provenge—what a costly cancer treatment says about future Medicare policy JD Chambers, PJ Neumann New England Journal of Medicine 364 (18), 1687-1689, 2011 | 81 | 2011 |
| Medicare’s enduring struggle to define “reasonable and necessary” care PJ Neumann, JD Chambers N Engl J Med 367 (19), 1775-1777, 2012 | 67 | 2012 |
| The influence of time horizon on results of cost-effectiveness analyses DD Kim, CL Wilkinson, EF Pope, JD Chambers, JT Cohen, PJ Neumann Expert review of pharmacoeconomics & outcomes research 17 (6), 615-623, 2017 | 65 | 2017 |
| Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia T Thorat, PJ Neumann, JD Chambers Journal of managed care & specialty pharmacy 24 (7), 632-642, 2018 | 62 | 2018 |
| Specialty drug coverage varies across commercial health plans in the US JD Chambers, DD Kim, EF Pope, JS Graff, CL Wilkinson, PJ Neumann Health Affairs 37 (7), 1041-1047, 2018 | 59 | 2018 |
| Payer coverage policies for multigene tests KA Phillips, PA Deverka, JR Trosman, MP Douglas, JD Chambers, ... Nature biotechnology 35 (7), 614-617, 2017 | 55 | 2017 |
| Private payers disagree with Medicare over medical device coverage about half the time JD Chambers, M Chenoweth, T Thorat, PJ Neumann Health Affairs 34 (8), 1376-1382, 2015 | 45 | 2015 |
| Medicare is scrutinizing evidence more tightly for national coverage determinations JD Chambers, M Chenoweth, MJ Cangelosi, J Pyo, JT Cohen, ... Health Affairs 34 (2), 253-260, 2015 | 43 | 2015 |
| What can we learn from the US expanded end-stage renal disease bundle? JD Chambers, DE Weiner, SK Bliss, PJ Neumann Health Policy 110 (2-3), 164-171, 2013 | 42 | 2013 |
| Therapies for advanced cancerspose a special challenge for health technology assessment organizations in many countries PJ Neumann, SK Bliss, JD Chambers Health Affairs 31 (4), 700-708, 2012 | 41 | 2012 |
| Factors predicting Medicare national coverage: an empirical analysis JD Chambers, S Morris, PJ Neumann, MJ Buxton Medical Care 50 (3), 249-256, 2012 | 39 | 2012 |
| Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs JD Chambers, MC Silver, FC Berklein, JT Cohen, PJ Neumann Journal of general internal medicine 35, 2629-2636, 2020 | 38 | 2020 |
| A review of empirical analyses of disinvestment initiatives JD Chambers, MN Salem, BN D’Cruz, P Subedi, SJ Kamal-Bahl, ... Value in Health 20 (7), 909-918, 2017 | 38 | 2017 |
| An assessment of the methodological quality of published network meta-analyses: a systematic review JD Chambers, H Naci, OJ Wouters, J Pyo, S Gunjal, IR Kennedy, ... PloS one 10 (4), e0121715, 2015 | 38 | 2015 |
| Drugs cleared through the FDA’s expedited review offer greater gains than drugs approved by conventional process JD Chambers, T Thorat, CL Wilkinson, PJ Neumann Health Affairs 36 (8), 1408-1415, 2017 | 34 | 2017 |
| Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain JD Chambers, KE May, PJ Neumann Health Affairs 32 (6), 1109-1115, 2013 | 33 | 2013 |
